Literature DB >> 24288410

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Annkristin Heine1, Peter Brossart, Dominik Wolf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24288410     DOI： 10.1182/blood-2013-10-531103

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  46 in total

1.  Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.

Authors:  Caroline Ebert; Florian Perner; Denise Wolleschak; Tina M Schnöder; Thomas Fischer; Florian H Heidel
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

2.  Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

Authors:  David E Spaner; Guizhei Wang; Lindsay McCaw; Yanmei Li; Patricia Disperati; Mary-Ann Cussen; Yonghong Shi
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

Review 3.  Efficacy of ruxolitinib for myelofibrosis.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2014-05-24       Impact factor: 3.889

4.  Get a grip on immune cells by inhibiting JAKs.

Authors:  Kathrin Schönberg; Janna Rudolph; Sowmya Parampalli Yajnanarayana; Dominik Wolf
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

Review 5.  Austrian recommendations for the management of polycythemia vera.

Authors:  Sonja Burgstaller; Veronika Buxhofer-Ausch; Thamer Sliwa; Christine Beham-Schmid; Günther Gastl; Klaus Geissler; Thomas Melchardt; Maria Krauth; Peter Krippl; Andreas Petzer; Holger Rumpold; Albert Wölfler; Heinz Gisslinger
Journal:  Wien Klin Wochenschr       Date:  2018-07-19       Impact factor: 1.704

6.  A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Tapan Kadia; Jorge Cortes; Gautam Borthakur; Kate Newberry; Guillermo Garcia-Manero; Farhad Ravandi; Elias Jabbour; Sara Dellasala; Sherry Pierce; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-09-17

7.  Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Authors:  Mohamed Shanavas; Uday Popat; Laura C Michaelis; Veena Fauble; Donal McLornan; Rebecca Klisovic; John Mascarenhas; Roni Tamari; Murat O Arcasoy; James Davies; Usama Gergis; Oluchi C Ukaegbu; Rammurti T Kamble; John M Storring; Navneet S Majhail; Rizwan Romee; Srdan Verstovsek; Antonio Pagliuca; Sumithira Vasu; Brenda Ernst; Eshetu G Atenafu; Ahmad Hanif; Richard Champlin; Paremeswaran Hari; Vikas Gupta
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-19       Impact factor: 5.742

8.  [Guidelines for vaccination of immunocompromised individuals].

Authors:  Ursula Wiedermann; Harald H Sitte; Heinz Burgmann; Alexander Eser; Petra Falb; Heidemarie Holzmann; Maria Kitchen; Marcus Köller; Herwig Kollaritsch; Michael Kundi; Hans Lassmann; Ingomar Mutz; Winfried F Pickl; Elisabeth Riedl; Maria Sibilia; Florian Thalhammer; Barbara Tucek; Werner Zenz; Karl Zwiauer
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

9.  Maybe we don't know JAK?

Authors:  Luis J Schwarz; Justin M Balko
Journal:  Mol Cell Oncol       Date:  2016-05-31

10.  Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.

Authors:  Radhika Gangaraju; Jihyun Song; Soo Jin Kim; Tsewang Tashi; Brandi N Reeves; Krishna M Sundar; Perumal Thiagarajan; Josef T Prchal
Journal:  Blood Adv       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.